Research News

ASH 2021: Polatuzumab Vedotin Reduces Risk for Disease Progression in Previously Untreated Diffuse Large B-Cell Lymphoma

In the phase III POLARIX study, a team of investigators led by LRF Scientific Advisory Board (SAB) member Christopher R. Flowers, MD, MSc of the University of Texas MD Anderson Cancer Center compared the efficacy of standard R-CHOP with that of a modified drug regimen, in which vincristine was replaced with the antibody-drug conjugate polatuzumab vedotin (pola-R-CHP).

ASH 2021: Minimal Residual Disease Kinetics Identified as a Predictor of Zanubrutinib-Obinutuzumab-Venetoclax Treatment Response in CLL

Minimal residual disease (MRD) kinetics were found to be predictive of achievement and durability of undetectable MRD with zanubrutinib-obinutuzumab-venetoclax (BOVen) treatment in patients with chronic lymphocytic leukemia (CLL), according to trial results presented by LRF grantee Jacob D. Soumerai, MD of Massachusetts General Hospital Cancer Center.

ASH 2021: High MCL35 Score Is Predictive of Poor Survival in Older Patients with Mantle Cell Lymphoma Treated with Bendamustine-Rituximab

In a study funded in part by LRF and led by LRF Scientific Advisory Board (SAB) and Mantle Cell Lymphoma Consortium (MCLC) member Lisa M. Rimsza, MD, of Mayo Clinic, Phoenix, researchers examined the prognostic value of the MCL35 assay in older patients (aged 65-93) with MCL who were treated with frontline bendamustine (Treanda) plus rituximab (Rituxan).

Beyond Barriers

Undeterred by barriers and challenges associated with lymphoma and the medical field, Dr. Sonali Smith’s work in the clinic and research realms, and natural-born leadership puts her at the forefront of advancing cures for this disease.